Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 3/20 | 0.39 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | CEL | P19835 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.36 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30152751 | 1.00 | NUDT1 (0.42) | NUDT1BACE1HSP90AA1FEN1ACMSD | |
| SCHEMBL4609516 | 0.98 | NUDT1 (0.40) | NUDT1BACE1HSP90AA1FEN1ACMSD | |
| SCHEMBL7861267 | 0.86 | NUDT1 (0.44) | NUDT1BACE1HSP90AA1FEN1ACMSD | |
| SCHEMBL6863507 | 0.86 | NUDT1 (0.44) | NUDT1BACE1HSP90AA1FEN1ACMSD | |
| SCHEMBL10607806 | 0.82 | NUDT1 (0.46) | NUDT1BACE1HSP90AA1FEN1ACMSD | |
| SCHEMBL4301114 | 0.81 | HTR2C (0.44) | NUDT1BACE1HSP90AA1HDAC4HDAC2 | |
| SCHEMBL11709403 | 0.81 | NUDT1 (0.39) | NUDT1BACE1HSP90AA1ACMSDADRB2 | |
| SCHEMBL8954635 | 0.81 | HTR2C (0.44) | NUDT1BACE1HSP90AA1HDAC4HDAC2 | |
| SCHEMBL11764867 | 0.79 | NUDT1 (0.41) | NUDT1BACE1HSP90AA1FEN1ACMSD | |
| SCHEMBL28645757 | 0.79 | NUDT1 (0.45) | NUDT1BACE1HSP90AA1FEN1ACMSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101184722-B | Novel resorcinol derivatives for skin | UNILEVER NV | 2011-06-22 | — | — | CN | claimed |
| US-7468464-B2 | Resorcinol derivatives for skin | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) | 2008-12-23 | — | — | US | claimed |
| EP-1861353-B1 | NOVEL RESORCINOL DERIVATIVES FOR SKIN | UNILEVER PLC (GB) | 2008-10-08 | — | — | EP | claimed |
| US-20080131382-A1 | Novel Resorcinol Derivatives for Skin | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) | 2008-06-05 | — | — | US | claimed |
| CN-101184722-A | Novel resorcinol derivatives for skin | UNILEVER HOME & PERSONAL CARE (NL) | 2008-05-21 | — | — | CN | claimed |
| CN-101175711-A | Novel resorcinol derivatives | UNILEVER PLC (NL) | 2008-05-07 | — | — | CN | claimed |
| EP-1861353-A1 | NOVEL RESORCINOL DERIVATIVES FOR SKIN | UNILEVER PLC (GB) | 2007-12-05 | — | — | EP | claimed |
| EP-1858835-A1 | NOVEL RESORCINOL DERIVATIVES | UNILEVER PLC (GB) | 2007-11-28 | — | — | EP | claimed |
| US-20060210498-A1 | Novel resorcinol derivatives for skin | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006097223-A1 | NOVEL RESORCINOL DERIVATIVES | UNILEVER PLC (GB) | 2006-09-21 | — | — | WO | claimed |
| WO-2006097224-A1 | NOVEL RESORCINOL DERIVATIVES FOR SKIN | UNILEVER PLC (GB) | 2006-09-21 | — | — | WO | claimed |
| US-20060210497-A1 | Novel resorcinol derivatives | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2006-09-21 | — | — | US | claimed |
| US-20220073736-A1 | POLYCARBONATE COMPOSITION, PREPARATION METHOD AND APPLICATION THEREOF | KINGFA SCI. & TECH. CO., LTD. (CN) | 2022-03-10 | — | — | US | disclosed |
| EP-3889219-A1 | POLYCARBONATE COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | KINGFA SCI. & TECH. CO., LTD. (CN) | 2021-10-06 | — | — | EP | disclosed |
| CN-109796736-B | Polycarbonate composition and preparation method and application thereof | 金发科技股份有限公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-101184722-B | Novel resorcinol derivatives for skin | UNILEVER NV | 2011-06-22 | — | — | CN | disclosed |
| US-20060210498-A1 | Novel resorcinol derivatives for skin | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006097223-A1 | NOVEL RESORCINOL DERIVATIVES | UNILEVER PLC (GB) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006097224-A1 | NOVEL RESORCINOL DERIVATIVES FOR SKIN | UNILEVER PLC (GB) | 2006-09-21 | — | — | WO | disclosed |
| US-20060210497-A1 | Novel resorcinol derivatives | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080131382-A1 | Novel Resorcinol Derivatives for Skin | NR1H2, CYP1B1, NR0B1 | NUDT1 1098/4885BACE1 464/4885HSP90AA1 3078/4885 |
| US-20060210498-A1 | Novel resorcinol derivatives for skin | NR1H2, CYP1B1, NR0B1 | NUDT1 1098/4885BACE1 464/4885HSP90AA1 3078/4885 |
| US-20060210497-A1 | Novel resorcinol derivatives | NR1H2, DEGS1, NR1H3 | NUDT1 1482/4885BACE1 369/4885HSP90AA1 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.